TrialAnnals of hematology2012

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

Amanda Cashen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.